SA
IOVA icon

Sanctuary Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Sanctuary Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.3K Buy
13,284
+2,316
+21% +$8.8K ﹤0.01% 2765
2026
Q1 		$38.5K Buy
+10,968
New +$35.1K ﹤0.01% 2504
2025
Q3 		– Sell
-34,707
Closed -$59.7K – 2481
2025
Q2 		$59.7K Buy
+34,707
New +$86.4K ﹤0.01% 2303

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Sanctuary Advisors's IOVA Position: Q2 2026 in Review

Sanctuary Advisors increased its Iovance Biotherapeutics (IOVA) stake by 21% in Q2 2026, buying an estimated $8.8K and bringing the position to 13,284 shares worth $55.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2765.

Sanctuary Advisors first reported a position in IOVA in Q2 2025 and has held it in 3 quarters since. The position peaked at $59.7K in Q2 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Sanctuary Advisors held 13,284 shares of Iovance Biotherapeutics worth $55.3K as of Q2 2026.
  • Sanctuary Advisors bought 2,316 Iovance Biotherapeutics shares in Q2 2026, an estimated $8.8K.
  • Iovance Biotherapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2765 holding.
  • Sanctuary Advisors first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • Sanctuary Advisors's Iovance Biotherapeutics position peaked at $59.7K in Q2 2025.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.